SCHEMBL13665115

SCHEMBL13665115

CC(C)(C)OC(=O)COc1ccc(Br)cc1C#N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AAK1 Q2M2I8 6/20 0.59
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
TP53 P04637 2/20 0.47
HSD17B10 Q99714 2/20 0.47
PTGDR2 Q9Y5Y4 3/20 0.46
ALDH1A1 P00352 5/20 0.42
HPGD P15428 3/20 0.42
TSHR P16473 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
MAPK1 P28482 1/20 0.41
XDH P47989 1/20 0.41
KDM4E B2RXH2 3/20 0.40
AR P10275 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30188569 1.00 AAK1 (0.59) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL13665117 0.92 AAK1 (0.54) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL13665112 0.85 HSD17B10 (0.51) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL15518170 0.85 NPC1 (0.56) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL13665133 0.84 ALDH1A1 (0.50) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL6213275 0.84 NPC1 (0.47) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL13665113 0.83 NPC1 (0.68) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL15074081 0.83 POLB (0.48) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL13665111 0.81 NPC1 (0.50) AAK1NPC1RAB9ATP53HSD17B10
SCHEMBL28979210 0.81 AAK1 (0.56) AAK1NPC1RAB9ATP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
CN-112543764-A Amide compound with BET proteolysis induction effect and medical application thereof 田边三菱制药株式会社 2021-03-23 CN disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 US disclosed
US-7605158-B2 Carbamoyl-type benzofuran derivatives MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-10-20 US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed
US-20090209511-A1 Benzofuran Derivatives KAWAGUCHI TAKAYUKI 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB AAK1 1332/4885NPC1 3288/4885RAB9A 2761/4885
US-20090209511-A1 Benzofuran Derivatives F12, F2, F3 AAK1 3597/4885NPC1 3431/4885RAB9A 4600/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB AAK1 1383/4885NPC1 3072/4885RAB9A 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.